Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy

被引:8
|
作者
Nakajima, Yuki [1 ]
Tomita, Naoto [1 ]
Itabashi, Megumi [2 ]
Miyashita, Kazuho [3 ]
Watanabe, Reina [4 ]
Miyazaki, Takuya [1 ]
Tachibana, Takayoshi [1 ]
Takasaki, Hirotaka [4 ]
Kawasaki, Rika [3 ]
Tanaka, Masatsugu [2 ]
Hashimoto, Chizuko [5 ]
Yamazaki, Etsuko [1 ]
Taguchi, Jun [6 ]
Fujimaki, Katsumichi [3 ]
Sakai, Rika [4 ]
Fujita, Hiroyuki [6 ]
Fujisawa, Shin [2 ]
Harano, Hiroshi [7 ]
Motomura, Shigeki [4 ]
Ishigatsubo, Yoshiaki [1 ]
机构
[1] Yokohama City Univ, Grad Sch Med, Dept Internal Med & Clin Immunol, Yokohama, Kanagawa 2360004, Japan
[2] Yokohama City Univ, Med Ctr, Dept Hematol, Yokohama, Kanagawa 2360004, Japan
[3] Fujisawa City Hosp, Dept Hematol Immunol, Fujisawa, Kanagawa, Japan
[4] Kanagawa Canc Ctr, Dept Med Oncol, Yokohama, Kanagawa 2410815, Japan
[5] Yamato Municipal Hosp, Dept Hematol Oncol, Yamato, Japan
[6] Shizuoka Red Cross Hosp, Dept Hematol, Shizuoka, Japan
[7] Yokosuka City Hosp, Dept Hematol, Yokosuka, Kanagawa, Japan
关键词
Diffuse large B-cell lymphoma; Infra-diaphragmatic; Supra-diaphragmatic; Prognostic factor; Gastrointestinal involvement; EXTRANODAL INVOLVEMENT;
D O I
10.1016/j.leukres.2014.11.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The prognostic implications of infra-diaphragmatic (InD) versus supra-diaphragmatic (SpD) primary lesions in limited-stage diffuse large B-cell lymphoma (DLBCL) remains unknown. This retrospective study aimed to assess the prognostic impact of spD and InD lesions as well as presence of gastrointestinal (GI) involvements in adults with limited-stage DLBCL. We analyzed data from 178 patients with limited-stage DLBCL who were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy at 7 institutions of the Yokohama City University Hematology Group between 2003 and 2009. The median age was 63 years (range, 18-80 years). The primary sites were SpD in 109 patients, and InD in 69. No statistical differences in progression-free survival (PFS) or overall survival (OS) were observed between patients with SpD lesions and those with InD lesions. However, when patients with SpD lesions, InD lesions with (n = 35), and without (n = 34) GI involvement were compared, the presence of GI lesions was associated with favorable PFS. The multivariate analysis revealed that SpD or InD localization had no independent effect on PFS or OS, whereas the presence of GI lesions was correlated with favorable PFS (P = 0.024, HR 0.09). (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:198 / 203
页数:6
相关论文
共 50 条
  • [31] R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma
    Tomita, Naoto
    Takasaki, Hirotaka
    Miyashita, Kazuho
    Fujisawa, Shin
    Ogusa, Eriko
    Matsuura, Shiro
    Kishimoto, Kumiko
    Numata, Ayumi
    Fujita, Atsuko
    Ohshima, Rika
    Kuwabara, Hideyuki
    Hagihara, Maki
    Hashimoto, Chizuko
    Takemura, Sachiya
    Koharazawa, Hideyuki
    Yamazaki, Etsuko
    Fujimaki, Katsumichi
    Taguchi, Jun
    Sakai, Rika
    Ishigatsubo, Yoshiaki
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (03) : 383 - 388
  • [32] R-CHOP Therapy for diffuse large B-cell Lymphoma of leg-type
    Abeck, F.
    Booken, N.
    Schneider, S. W.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 12 - 12
  • [33] Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP
    Hill, Brian T.
    Kahl, Brad
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (09) : 805 - 812
  • [34] Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
    Guo, Wei
    Zhang, Wenxian
    Liu, Chunshui
    Song, Yuanyuan
    Bai, Ou
    PLOS ONE, 2015, 10 (06):
  • [35] Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy
    Kenjiro Mitsuhashi
    Akihiro Masuda
    Yan-Hua Wang
    Masayuki Shiseki
    Toshiko Motoji
    International Journal of Hematology, 2014, 100 : 88 - 95
  • [36] Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy
    Mitsuhashi, Kenjiro
    Masuda, Akihiro
    Wang, Yan-Hua
    Shiseki, Masayuki
    Motoji, Toshiko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (01) : 88 - 95
  • [37] Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy
    Moo-Kon Song
    Joo-Seop Chung
    Dong-Yeop Shin
    Sung-Nam Lim
    Gyeong-won Lee
    Jae-Cheol Choi
    Won-Young Park
    So-Yeon Oh
    Annals of Hematology, 2017, 96 : 17 - 23
  • [38] Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy
    Song, Moo-Kon
    Chung, Joo-Seop
    Shin, Dong-Yeop
    Lim, Sung-Nam
    Lee, Gyeong-won
    Choi, Jae-Cheol
    Park, Won-Young
    Oh, So-Yeon
    ANNALS OF HEMATOLOGY, 2017, 96 (01) : 17 - 23
  • [39] Primary Cutaneous Diffuse Large B-cell Lymphoma Successfully Treated With R-CHOP Chemotherapy
    Alghamdi, Wafa M.
    Aljehani, Fawaz H.
    Alharthi, Abdullah M.
    Bakhsh, Reda I.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [40] R-CHOP compared with CHOP in patients with diffuse large B-cell lymphoma (DLCL): Russian experience
    Poddubnaya, I.
    Osmanov, E.
    Babicheva, L.
    Tumyan, G.
    Sorokin, E.
    Stefanov, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)